Anuja Vyas, MD
Pulmonary Disease · la Jolla, CANPI 1316171283
Payments from drug & device makers
Across 43 payments — averaging $818.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$34K
- Pulmonx Corporation$204
- Edwards Lifesciences$197
- Pinnacle Biologics, Inc$196
- Olympus America Inc.$133
- Novo Nordisk$100
- plus $34 from 2 others
What the payments were for
- Speaking & faculty fees$16,50047%
- Travel & lodging$8312%
- Food & beverage$3,2139%
- Education$14,64442%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 34 | $34,324 |
| Pulmonx Corporation | 2 | $204 |
| Edwards Lifesciences | 1 | $197 |
| Pinnacle Biologics, Inc | 2 | $196 |
| Olympus America Inc. | 1 | $133 |
| Novo Nordisk | 1 | $100 |
| United Therapeutics Corporation | 1 | $19 |
| Cook Medical LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,188 in reported general payments places this provider in the 85th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZemairaAlpha-1-Proteinase Inhibitor | 13 | $166,066 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 134 | $113,830 |
| Dupixent PenDupilumab | 11 | $42,186 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $6,713 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $6,320 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,498 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,059 |
| Arnuity ElliptaFluticasone Furoate | 11 | $3,172 |
| Montelukast Sodium | 41 | $928 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $628 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $539 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 20 | $531 |
| Azelastine Hcl | 16 | $531 |
| Ipratropium Bromide | 19 | $507 |
| Prednisone | 49 | $264 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in la Jolla
- Timothy Fernandesla Jolla$564K
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
- Namita SoodSacramento$3.7M
- Edward FedermanSan Diego$3.6M
- Sanjay VadgamaSherman Oaks$3.3M
- Rajan SaggarLos Angeles$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.